This article is more than 5 years old. Information may no longer be current.
RegeneRx to begin enrolling patients in phase 2 dry eye trial
Click Here to Manage Email Alerts
ROCKVILLE, Md. — RegeneRx Biopharmaceuticals announced that it will begin a phase 2 clinical trial of its RGN-259 eye drop in 72 patients with dry eye syndrome, a company press release said.
The double-masked, placebo-controlled trial will test the safety and efficacy of RGN-259, RegeneRx’s proprietary preservative-free eye drop, against placebo. Patients will receive RGN-259 or placebo twice daily for 30 days. Dry eye signs and symptoms, including the degree of ocular surface damage, ocular itching, burning and inflammation, will be measured periodically during the treatment period, according to the release.
RegeneRx anticipates enrollment of the first patients to begin in mid-August. Preliminary data from the study is projected to be released in October.